evipedia.ai
← Back

Transcranial Electric Stimulation for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Transcranial electric stimulation, a family of drug-free techniques that pass a weak current through scalp electrodes, is used, including at home, to support mood and memory with age. Depression has the strongest evidence: modest improvement over placebo stimulation, but none when added to ongoing antidepressants in a large trial. Some approaches give older adults modest, time-limited memory gains. It looks low-risk within tested limits; long-term brain-health benefits remain uncertain. (Full Review)

Protocol

Depression, home tDCS
2 mA for 30 minutes
Anode over left, cathode over right dorsolateral prefrontal cortex; five sessions weekly for 3 weeks, then three weekly for 7 weeks
Memory in older adults, tACS
20 minutes daily for 4 consecutive days
High-definition electrode arrangement; low-frequency parietal stimulation for working memory, high-frequency prefrontal stimulation for long-term memory
Long-term prevention, tDCS plus cognitive remediation
Five days weekly for 8 weeks
Then twice-yearly 5-day boosters with daily home cognitive training
Time to effect
Mood
By week 4
Separated from placebo stimulation, then grew through week 10 of repeated sessions
Memory, tACS
By day 2–4
Gains after 4 days persisted at one month
Pain
Short-term
tDCS in chronic pain; cranial electrotherapy showed no effect

Benefits

Contraindications
  • People with bipolar disorder or a past episode of mania or hypomania
  • People with epilepsy or prior unprovoked seizures
  • People with metal or electronic implants in the head, or pacemakers
  • People with broken skin, eczema or lesions at electrode sites
    •
Key Interactions
  • Sodium and calcium channel blockers (carbamazepine, flunarizine): excitatory protocols are expected to be ineffective during use
  • NMDA receptor antagonists, including the over-the-counter cough suppressant dextromethorphan: prevented lasting after-effects of tDCS
  • SSRIs (citalopram, sertraline, escitalopram): citalopram enhanced excitatory after-effects; raised mania risk
  • Benzodiazepines (lorazepam, clonazepam, diazepam): use associated with worse antidepressant response to tDCS
  • Dopaminergic drugs (levodopa, bromocriptine): excitatory protocols may lose effect
  • Cholinesterase inhibitors (rivastigmine, donepezil): excitatory protocols may lose effect
  • Nicotine (nasal spray, patches, cigarettes): nicotine spray abolished the intended effect of excitatory tDCS
  • Stimulants (amphetamine, caffeine): amphetamine enhanced excitatory after-effects; caffeine can distort stimulation results
    •
Theoretical (inferred from mechanism)
  • Serotonergic supplements (St John's wort, 5-HTP, SAMe): could add antidepressant effect and mania risk
  • Other sodium-channel-blocking anticonvulsants (lamotrigine, oxcarbazepine, phenytoin): could blunt excitatory tDCS effects
  • Alcohol and sedative sleep aids (zolpidem, eszopiclone): could blunt the response to stimulation
    •

Risk & Side Effects

  • High: Mild transient sensations, headache, dizziness and skin redness or dryness
    •
  • Medium: Treatment-emergent mania or hypomania in depression; cognitive trade-offs and protocol-induced impairment; skin burns under electrodes
    •
  • Low: Seizures
    •
  • Speculative: Unknown effects of years-long repeated use
    •

Monitoring

Marker Target Why
PHQ-9 depression score No established target; track change from own baseline Expected to change; worsening is a safety signal
Mania symptom screen No established target; track new elevated mood or reduced need for sleep Safety check: new symptoms stop use
Electrode-site skin condition No established target; track persisting redness, blisters or lesions Safety check: lesions stop use
Cognitive test battery No established target; track change from own baseline Expected to change with memory protocols

Cadence: Skin checks before and after every session; mood and mania screens weekly for the first 6 weeks, then every 2 weeks through week 10 of a course, then every 3 months during maintenance; cognitive testing at baseline, at the end of a course, and at 1 and 6 months afterward.

Qualitative Assessment

  • Mood stability and day-to-day energy
  • Sleep quality and sleep onset
  • Mental clarity, word-finding and memory in daily tasks
  • Pain intensity, where pain is a target
  • Scalp comfort during and after sessions
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.